Trial 0C-16-1


Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB™ FS102 in HER2 positive Solid Tumors

Type: Treatment
Phase: Phase I
Status: Not Open (Closed)
Treatments: Immunomodulator
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Alicia Bogardus, Coordinator, Cristina De Leon, R.N., Lisa Earnest, R.N., Anayansi Miloud, D.M., Xiomara Menendez, Coordinator, Jubilee Acap, Coordinator, Khatchik Karakozian, D.M., Pam McTague, R.N., Hany Ghattas, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.